Cargando…
The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada
This article identifies the potential sources of inequity in three stages of integrating cystic fibrosis personalized medicines into the Canadian healthcare system and proposes mitigating strategies: (1) clinical research and diagnostic testing; (2) regulatory oversight and market authorization; and...
Autores principales: | Shemie, Genevieve, Nguyen, Minh Thu, Wallenburg, John, Ratjen, Felix, Knoppers, Bartha Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151662/ https://www.ncbi.nlm.nih.gov/pubmed/34067090 http://dx.doi.org/10.3390/jpm11050382 |
Ejemplares similares
-
“The Stakes Are Higher”- Patient and Caregiver Perspectives on Cystic Fibrosis Research and Personalized Medicine
por: Knoppers, Terese, et al.
Publicado: (2022) -
Perspectives on the translation of in-vitro studies to precision medicine in Cystic Fibrosis
por: Dumas, Marie-Pier, et al.
Publicado: (2021) -
Designing Clinical Trials for Anti-Inflammatory Therapies in Cystic Fibrosis
por: Perrem, Lucy, et al.
Publicado: (2020) -
Letting It All Out: Neutrophils in Early Cystic Fibrosis Airway Inflammation
por: Perrem, Lucy, et al.
Publicado: (2019) -
L-Ornithine Derived Polyamines in Cystic Fibrosis Airways
por: Grasemann, Hartmut, et al.
Publicado: (2012)